A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
List view / Grid view
Filter the results
The study shows how drug-like small molecules inhibit the activity of Transient Receptor Potential Canonical 1/4/5 (TRPC1/4/5) channels and could transform the development of future therapies.
Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
Dr Mike Tocci discusses how pharmacogenomics can revolutionise medical research and improve the efficacy and quality of drugs.
The mechanism in the brain connecting chronic pain and depression could lead to treatments for both, according to researchers.
A study has discovered a molecule key in neuronal growth that could be used as a drug target to treat anxiety-related diseases.
Researchers have identified a tiny hidden pocket on the NMDA receptor that could be targeted to treat strokes and seizures...
Researchers have found that a single dose of cannabidiol in rats with symptoms of depression was highly effective at eliminating symptoms...
18 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Anti-inflammatory drugs, like those used to treat rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression...
18 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Researchers at Imperial College have studied how the psychedelic substance LSD works in the brain and the effect on speech and language, discovering that...